Old Dominion University

ODU Digital Commons
Mathematics & Statistics Faculty Publications

Mathematics & Statistics

2022

Robust Meta-Analysis for Large-Scale Genomic Experiments
Based on an Empirical Approach
Sinjini Sikdar
Old Dominion University, ssikdar@odu.edu

Follow this and additional works at: https://digitalcommons.odu.edu/mathstat_fac_pubs
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Genetics
Commons, Genomics Commons, and the Medical Genetics Commons

Original Publication Citation
Sikdar, S. (2022). Robust meta-analysis for large-scale genomic experiments based on an empirical
approach. BMC Medical Research Methodology, 22, 1-12, Article 43. https://doi.org/10.1186/
s12874-022-01530-y

This Article is brought to you for free and open access by the Mathematics & Statistics at ODU Digital Commons. It
has been accepted for inclusion in Mathematics & Statistics Faculty Publications by an authorized administrator of
ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.

(2022) 22:43
Sikdar BMC Medical Research Methodology
https://doi.org/10.1186/s12874-022-01530-y

BMC Medical Research
Methodology

Open Access

RESEARCH

Robust meta-analysis for large-scale
genomic experiments based on an empirical
approach
Sinjini Sikdar*

Abstract
Background: Recent high-throughput technologies have opened avenues for simultaneous analyses of thousands
of genes. With the availability of a multitude of public databases, one can easily access multiple genomic study results
where each study comprises of significance testing results of thousands of genes. Researchers currently tend to combine this genomic information from these multiple studies in the form of a meta-analysis. As the number of genes
involved is very large, the classical meta-analysis approaches need to be updated to acknowledge this large-scale
aspect of the data.
Methods: In this article, we discuss how application of standard theoretical null distributional assumptions of the
classical meta-analysis methods, such as Fisher’s p-value combination and Stouffer’s Z, can lead to incorrect significant
testing results, and we propose a robust meta-analysis method that empirically modifies the individual test statistics
and p-values before combining them.
Results: Our proposed meta-analysis method performs best in significance testing among several meta-analysis
approaches, especially in presence of hidden confounders, as shown through a wide variety of simulation studies and
real genomic data analysis.
Conclusion: The proposed meta-analysis method produces superior meta-analysis results compared to the standard
p-value combination approaches for large-scale simultaneous testing in genomic experiments. This is particularly
useful in studies with large number of genes where the standard meta-analysis approaches can result in gross false
discoveries due to the presence of unobserved confounding variables.
Keywords: Meta-analysis, Fisher’s p-value combination, Empirical null distribution, Weighted Z statistic, Simultaneous
hypothesis testing
Background
In genomic experiments and association studies, metaanalysis is a popular tool for pooling results from multiple experiments and research studies to reach an
overall decision. Due to the rapid progress in technology,
there has been major development of high-throughput
*Correspondence: ssikdar@odu.edu
Department of Mathematics and Statistics, Old Dominion University,
Norfolk, VA, USA
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genomic assays. It is now possible to analyze hundreds
or thousands of genes at the same time. Thus, the paradigm of simultaneous inference has transformed a
lot over the past few years. Moreover, huge number
of available datasets in public repositories and databases have enabled researchers to assimilate large-scale
genomic information from multiple studies in the form
of meta-analysis [1–3]. Since the sample sizes of individual genomic experiments are generally small compared to the number of genes resulting in loss of power
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of statistical detection after adjusting for multiple testing, meta-analysis of multiple genomic experiments has
been recognized as the appropriate method in order to
achieve adequate sample sizes and optimal power for
statistical detection [4, 5]. Meta-analysis has also gained
popularity as a powerful tool for combining results from
multiple genome-wide association studies [6, 7]. However, current meta-analysis approaches cannot accommodate the new large-scale aspect of the underlying
inference of genomic experiments. The traditional metaanalysis methods, initially developed for combining
results of significance testing from experiments involving only a few candidate genes, are still being applied to
current large-scale experiments involving thousands of
genes [8–10]. There are two main approaches for classical meta-analysis methods [11]. The first approach is
to combine p-values of significance testing from multiple studies, and the second approach is to combine the
model-based effect sizes from different studies. While
both the approaches have their own advantages and disadvantages, the p-value combination methods are more
flexible as they require less assumptions from the component studies and allows results from the component
studies to be combined even when the individual effect
sizes and standard errors are unavailable or are in different units. Some classical p-value combination methods include Fisher’s p-value combination [12], Stouffer’s
Z-test [13], and the weighted variations of these methods [14]. In this paper we will focus on the meta-analysis
methods of p-value combination.
One of the main assumptions of the classical p-value
combination methods is that for a given gene, the p-values obtained from the component studies are individually
uniformly distributed under the null hypothesis. However, as pointed out by Efron [15], in large-scale multiple testing problems, the p-values may not be uniformly
distributed. Consequently, this raises questions on the
validity of the distributional assumptions of p-value combined test statistics of the classical approaches of Fisher
[12], Stouffer [13] and their variants. To apply these classical p-value combination approaches to large-scale significance testing, one needs to ensure that all the p-values
obtained from the individual studies are uniformly distributed. This is important in such large-scale hypothesis
testing frameworks since the aims of these experiments
differ from that of a traditional single hypothesis testing
scenario. In a single hypothesis test, one aims to reject an
uninteresting null hypothesis in favor of some interesting
alternative hypothesis with high power, e.g., 90%. However, in a large-scale genomic experiment, the number
of hypotheses can easily be as large as 10,000 because of
the same number of genes involved. In that case, the aim
is to identify a small subset of genes, usually much less
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than 10% of the total number of genes, which are of most
significance and are carried forward for further investigation. Thus, it is not expected from a large-scale multiple
hypotheses framework to reject 90% of the 10,000 null
hypotheses involved, unlike that of a single hypothesis
framework. Efron [15] points out that the advantage of
having thousands of null hypotheses in place of a single
null hypothesis is that one can estimate the null distribution empirically and do not need to carry out testing
based on some theoretical asymptotic null distribution.
Empirical null distribution can be very useful in large
observational studies since, unlike the theoretical null, it
can take into account the additional variation and moderate bias caused by some unobserved variables (e.g., batch
effects [16] or unmeasured confounder effects). Moreover, the problems caused by ignoring the effects of unobserved variables or potential confounders, and relying
on theoretical null distribution for testing, can be aggravated in meta-analysis of large-scale genomic studies as
discussed in Sikdar et al. [17]. In such a situation, even
though a meta-analysis method has high power, it can
lead to gross false discoveries of significant genes even
after applying standard multiple testing correction techniques [17]. Therefore, in order to reduce the false discovery rate, it is essential to build meta-analysis methods
involving large-scale hypothesis testing that are based on
empirically adjusted null distribution rather than a theoretically assumed null distribution.
The idea of drawing inference based on an empirical
null distribution, instead of a theoretical null distribution, was recently adopted in the context of meta-analysis by Sikdar et al. [17] and later applied in You et al.
[18]. The meta-analysis method of Sikdar et al. [17],
known as EAMA, modifies the classical Fisher’s p-value
combination method for large-scale genomic studies
by empirically adjusting the null distribution through
an empirical Bayes framework where the amount of
adjustment depends on the extent of discrepancy
between the empirical and the theoretical null distributions. However, EAMA was only limited to the classical
unweighted (equally weighted) Fisher’s p-value combination method which can perform poorly when there
are large variations among the component studies of
meta-analysis. Moreover, its performance can become
unstable in certain situations as shown through simulation studies in a later section. In this article we propose a meta-analysis method for large-scale genomic
experiments that implements a weighted p-value
combination approach while estimating the empirical
null distribution parameters through a recently developed Bayesian approach by van Iterson et al. [19] as
opposed to the empirical Bayes approach of EAMA.
Through a variety of simulated scenarios, we show that
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our proposed empirical null adjusted meta-analysis
method has robust performances and works best in
reducing false discoveries among several competing
approaches for large-scale genomic meta-analysis especially in the presence of hidden confounders. Moreover,
we demonstrate the utility of the proposed meta-analysis approach through a meta-analysis of lung cancer
genomic studies.
The rest of the paper is organized as follows. In the
Methods section, we describe the popular p-value
combination approaches, methods for empirical null
estimation, and our proposed combination of empirical null adjusted meta-analysis of large-scale simultaneous significance testing. In the Results section, we
construct various simulation settings to compare the
performances of our proposed meta-analysis approach
with that of the other competing approaches. We also
illustrate our approach through an application on a set
of lung cancer genomic studies. The article ends with a
discussion and a conclusion section.

Methods
Meta‑analysis using weighted Z‑scores

Suppose there are K independent studies and G genes
in each study. Here the idea is to detect the genes that
are related to the outcome of interest based on the
results from the K independent studies. In other words,
for each gene j, we want to test the overall null hypothesis Hj: gene j does not contribute to the outcome of
interest across all K independent studies, j = 1, 2, …, G.
The general principle in the meta-analysis framework is
to combine the results for each gene across the K independent studies to reach an overall decision for that
gene.
In this section, we focus on a widely used weighted
Z-score meta-analysis method based on p-values from
independent studies [14], which is defined as follows:
Suppose Ni denotes the sample size of study i, i = 1, 2,
…, K. Let Δij and pij denote the direction of effect and
the p-value for gene j from study i, respectively, i = 1, 2,
…, K; j = 1, 2, …, G. The weighted Z-score meta-analysis method converts the direction of effect and p-value
observed in each study for each gene into a signed
Z-score, which is defined as
)
(
pij
× Δij for gene j in study i;i = 1, 2, … , K ;j = 1, 2, … , G.
Zij = Φ−1 1 −
2

The signed Z-scores, for each gene, are then combined
across studies in a weighted sum where the weights
are proportional to the square-root of the sample size
for each study [13, 14]. That is, for a gene j, the overall
Z-score is defined as
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K
i=1 Zij wi
Zj = 
K
2
i=1 wi

√
where wi = Ni ; i = 1, 2, …, K, j = 1, 2, …, G.
Finally, an overall p-value for the gene j is obtained as
Pj = 2(1 − Φ(|−Zj|)), j = 1, 2, …, G.
Method for empirical estimation of null distribution

Suppose there are G null hypotheses (for example, corresponding to G genes) in a single study. Let the p-values
corresponding to the null hypotheses be denoted as p1,
p2, …, pG. Each p-value in the study can be converted into
z-score as zj = Φ−1( pj), j = 1, 2, …, G. Theoretically, the
null distribution of zj is N(0, 1), j = 1, 2, …, G.
However, the large-scale multiple testing situations
enable us to estimate the null distribution of zj, j = 1, 2,
…, G. In this section, we will discuss a Bayesian approach,
named BACON [19], for estimating the null distribution
empirically.
BACON assumes that the z-scores can be modeled by a
three-component normal mixture, where one of the components represents the empirical null distribution and
the other two components represent two separate nonnull distributions. Here, the z-scores close to the central
peak of the histogram are assumed to be generated from
the null distribution, whereas those towards the left and
right tails of the histogram are generated from the two
different alternative distributions. The three-component
normal mixture model is defined as follows:

f (z) =

3


pk φ(z, µk , σk )

k=1


where 3k=1 pk = 1 and φ(z, μk, σk) represent the density
of N(μk, σk2), k = 1, 2, 3. This method uses a Gibbs sampling scheme to estimate the parameters of the mixture
distribution, assuming conjugate prior distributions for
the parameters as givenbelow:
2
µk | σk 2 ∼ N k , στk ; σk2~InverseGamma(αk, βk) and
k

(p1, p2, p3)~Dirichlet(γ1, γ2, γ3), k = 1, 2, 3.
We considered the same hyper-priors as suggested by
van Iterson et al. [19]. The initial values are considered
based on the median and median absolute deviation of
the test statistics [19].
At each iteration the Gibbs sampling algorithm comprises of the following steps given that we have G genes
resulting in G z-scores of the form zj (j = 1, 2, …, G) and
the associated outcome values yj (j = 1, 2, …, G):
1) The
unobserved data
is
generated
as:

∼
xjk ∼ Multinomial π jk where πjk = pkφ(zj, μk, σk)
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∼

and π jk is the normalized proportion so that

∼
3
k=1 π jk = 1.
2) The following
quantities
G are calculated:

,

ηk = G
1
s
=
and
k
j=1 xjk �=0
j=1 yj 1 xjk �=0 ,

G
sk2 = j=1 y2j 1xjk �=0.
3) Samples are generated from the posterior distributions as follows:
pk ∼ Dirichlet(γk + ηk ); µk | σk 2 ∼ N

1
σk 2

∼ Ŵ αk + 21 (ηk + 1), 



k τk +sk σk 2 +sk
ηk +τk , ηk +τ
k

1

βk + 12 τk (µk −k )2 + 12 sk2



;

A total of 5000 iterations and a burn-in period of 2000
iterations are recommended.
Proposed meta‑analysis method based on empirically
modified weighted Z‑scores

In this section, we describe our proposed approach of
an empirically adjusted meta-analysis that combines
appropriately weighted modified z-values and computes
multiple testing corrected p-values where the modification involves transforming the raw z-values through
an empirical correction of the null distribution. Following are the detailed steps of our proposed meta-analysis
method.
Considering K independent studies and G genes in
each study, let zij denotes the signed z-score, obtained
through transformation from p-value pij and direction

p
of the effect estimates ∆ij as zij = −1 1 − 2ij × ij ,

i = 1, 2, …, K; j = 1, 2, …, G, as defined in the methods
section. Since, these z-scores zij may not follow N(0, 1)
under the null hypotheses, we empirically estimate the
parameters of the
of the z-scores using

 null distribution
BACON. Let fˆ0 µ̂B , σ̂B2 denote the BACON estimated
null distribution of the z-scores. Using the estimated
z −µ̂
null density, we define z̃ij = ij σ̂ B as the modified
B
z-score for gene j from study i, i = 1, 2, …, K; j = 1, 2, …,
G. The modified z-scores z̃ij s, expected to be standard
normally distributed under the null hypotheses, are
then meta-analyzed using the weighted Z-score method
as follows:
K
i=1 z̃ij wi

Zj = 
K
2
i=1 wi

√
for j = 1, 2, …, G; where wi = Ni , and Ni is the sample
size of the study i; i = 1, 2, …, K. The overall p-value for
gene j is obtained as Pj = 2(1 − Φ(|−Zj|)), j = 1, 2, …, G.
The final p-values, Pj s, are corrected for multiple testing
using the Benjamini-Hochberg (BH) method [20].

Alternative choices for empirical null adjusted p‑value
combinations

In this section we discuss Fisher’s p-value combination,
a popular alternative to the weighted Z-score combination, which directly combines the p-values instead of
transforming them into z-values. In addition, we briefly
discuss another potential choice for computing empirical null distribution through an empirical Bayes method
that was first proposed by Efron [15] and subsequently
adopted for meta-analysis in EAMA [17]. The reason for
our discussion of these methods is that one can potentially combine any of the two p-value/z-value combination approaches with any of the two empirical null
computation algorithms and each such combination
leads to a different empirical adjusted meta-analysis. We
compare the performances of each such combination to
our proposed meta-analysis method in our simulations.
We briefly discuss the Fisher’s p-value combination
method [12] and the empirical Bayes method for estimating null distribution [15] as follows.
Fisher’s p‑value combination

Fisher’s method combines p-values across independent
studies giving equal weights to all studies [12]. Assuming K independent studies and G genes in each study, for
gene j, the test statistic for the Fisher’s method is defined
as

Fj = 2

K 
i=1

 
−log pij , j = 1, 2, . . . , G

Under the null hypothesis that gene j does not contribute to the outcome of interest, the test statistic Fj follows a
χ2 distribution with 2K degrees of freedom, assuming that
the p-values pijs are independently uniformly distributed
on the interval [0, 1] for each j; i = 1, 2, …, K; j = 1, 2, …, G.
Empirical Bayes method for estimating null distribution

Efron [15] used an empirical Bayes model for estimating the null distribution of the z-scores. The z-scores
for the genes are classified into two classes – “uninteresting” if z is generated from the null distribution, and
“interesting” if z is generated from the non-null distribution with respective densities f0(z) and f1(z). Also, let the
prior probabilities of z belonging to the “uninteresting”
or “interesting” classes be denoted as p0 and p1 = 1 − p0,
respectively. The mixture density of the z-scores can be
defined as f(z) = p0f0(z) + p1f1(z).
Following Bayes theorem, the a posteriori probability
of belonging to the “uninteresting” class given z can be
defined as
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 p0 f0 (z)
P “uninteresting"| z =
f (z)

The aim is to estimate the null density, f0, from the central peak of the histogram of the z-scores. Assuming the
null density, f0 is N(δ0, σ02), where the mean δ0 is not necessarily 0 and standard deviation σ0 is not necessarily 1,
for all z-scores close to 0, we can write




1 z − δ0 2
log f (z) = −
+ constant
2
σ0
The parameter δ0 can be estimated as argmax(f(z)) and


− 21
d2
log
f
(z)
σ0 can be estimated as − dz
. However, the
2
δ̂0

estimate of σ0 obtained by directly differentiating the
spline estimate of log(f(z)) can be unstable. Therefore, one
more smoothing step is applied where a quadratic curve,
a0 + a1 xk + a2 xk2 is fitted by ordinary least squares to the
estimated log(fk) values, for xk within 1.5 units of the maxi1
mum δ0, which yields σ0 = [−2a2 ]− 2 . This approach of
estimating the null distribution is called “central-matching” approach. More details about this approach can be
found in Efron [15] and Efron [21]. This empirical Bayes
method of estimating null distribution is referred to as EB
method from now on.
Note that, incorporating EB adjustment into Fisher’s
p-value combination approach leads to the previously
mentioned EAMA method [17]. Following this approach,
one can also apply EB adjustments to the weighted
Z-scores method as well as BACON adjustments to Fisher’s p-value combination where each combination gives
rise to a different meta-analysis method. The last two
meta-analysis methods, namely, EB adjusted weighted
Z-score and BACON adjusted Fisher, are also new and
have not been explored before in the literature. In this
article we are implementing them for the first time and
will explore their performances as competing candidates
to our proposed meta-analysis method in various simulation settings in the next section. We will also compare the
performance of EAMA in that section.

Results
Simulation studies

To evaluate the performance of our proposed method,
we simulated continuous gene expression datasets for
multiple independent experiments. We considered three
simulation settings – setting 1, setting 2, and setting 3. In
setting 1 we assumed there exists no hidden variable or
confounder in the data. For setting 2, we assumed presence of a hidden variable which acts as a confounder, and
in setting 3 we assumed presence of a hidden variable
which does not act as a confounder. Details of the data
generation method are described below.
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We considered 10 independent experiments, i.e.
K = 10 and two groups of subjects. The total number of
genes in each experiment was 10,000, i.e. G = 10,000,
out of which 1000 genes were assumed to be differentially expressed between the two subject groups. The
log expression value, Yjlm, for the gene j, subject m in
group l was generated using a linear model as given
below.
Yjlm = 𝜇 + 𝛼j + 𝛽l + (𝛼𝛽)jl + 𝛾jlm + ejlm ; j = 1, 2, … , G, l = 1, 2, m = 1, 2, … , nl

where nl denotes the number of subjects in each group
,l = 1, 2. Here, μ denotes the general mean effect, αj
denotes the effect due to the gene j, βl denotes the effect
due to the group l, (αβ)jl denotes the interaction effect
between the gene j and group l, γjlm denotes the effect of
a hidden variable or confounder, which remains unaccounted during an analysis, on the gene j, subject m in
the group l, while ejlm denotes the error term.
For all simulations, we set μ = αj = βl = 0, for all j, l for
simplicity. The interaction terms (αβ)jl were generated
as: For j ≤ 400, (αβ)j1 =  − 4, (αβ)j2 = 4; for 401 ≤ j ≤ 1000,
(αβ)j1 = 4, (αβ)j2 =  − 4; and for j > 1000, (αβ)j1 = (αβ)j2 = 0.
Generation of the interaction terms in this way ensures
that only the first 1000 genes were differentially expressed
between the two subject groups.
We considered four sets of correlated genes in
each experiment as follows: S1 = {j : 1 ≤ j ≤ 1000},
S2 = {j : 4001 ≤ j ≤ 5000}, S3 = {j :
5001 ≤ j ≤ 5200}; and
S4 = {j : 8091 ≤ j ≤ 9100} and S = 4u=1 Su. We generated
correlated expression levels of the genes in the four clusters through the generation of the error terms, ejlm, as
⎧
⎪
ejlm = ⎨
⎪
⎩

1 (1)
√ e
2 jlm

+

(2)
ejlm

1 (2)
√ e
2 jlm

if j ∈ S
otherwise

j = 1, 2, … , G, l = 1, 2, m = 1, 2, … , nl

(1)

Here, ejlm were independently generated from N(0, 1).
(1)
We considered the same value of ejlm for all the genes
(2)
belonging to the same cluster. ejlm were generated independently from N(0, 22); j = 1, 2, …, G, l = 1, 2, m = 1, 2,
…, nl.
With the above choices of the parameters of the linear
model, we generated datasets for the following three simulation settings:
Setting 1: In this setting, we assumed that there does
not exist any effect of hidden variable or confounder.
So, γjlm = 0 for all j, l, m.
Setting 2: In this setting, we assumed that there
exists an effect of hidden variable which acts
as a confounder. Here, we generated γjlm as
γjlm = ujlmI(sjlm = 1), where sjlm were generated from
Bernoulli(0.4) and ujlm were generated depending
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on the gene, subject and also the experiment as follows:
⎧ �
�
for j ≤ 400
⎪ N −1 + i, 0.012
⎪
�
�
2
uj1m ∼ ⎨ N 2 + i, 0.01
for 401 ≤ j ≤ 1000 ; i = 1, 2, … , K ;m = 1, 2, … , n1
�
�
⎪
2
for j > 1000
⎪ N 5 + i, 0.01
⎩
⎧ �
�
for j ≤ 400
⎪ N 3 + i, 0.012
⎪ �
�
uj2m ∼ ⎨ N 6 + i, 0.012 for 401 ≤ j ≤ 1000 ; i = 1, 2, … , K ;m = 1, 2, … , n2
�
⎪ �
2
for j > 1000
⎪ N 9 + i, 0.01
⎩

Here, the effect of the hidden confounder varied
between the two groups of subjects, according to the different groups of genes and over different experiments.
Setting 3: In this setting, we assumed that there exists
an effect of hidden variable which does not act as
confounder. Therefore, we considered a simulation
setting where the distribution of the hidden variable
does not differ between the two subject groups. We
generated γjlm as γjlm = ujlmI(sjlm = 1), where sjlm were
generated from Bernoulli(0.4) distribution and ujlm
were generated as ujlm~N(5 + i, 0.012); i = 1, 2, …, K;
m = 1, 2, …, nl; l = 1, 2.
We considered different choices for the sample sizes
of the experiments and the two groups in each experiment in our simulations which will be discussed in the
later sections.
After generating the data for the three simulation settings in each experiment, we used the ‘limma’ package in
Bioconductor for testing for differential expression for
the genes between the two subject groups [22]. The raw
p-value and direction of effect for each gene, obtained
from ‘limma’, were stored. We applied our proposed
method (BACON-adjusted weighted Z-score) to identify
the significant set of genes. For comparison, we applied
EB adjusted weighted Z-score method, EAMA, BACONadjusted Fisher method, along with standalone Fisher’s
method and weighted Z-score method without any
empirical adjustments to identify the significant genes.
A gene is identified as differentially expressed if the BH
adjusted p-value is less than 0.05.
The performance of our proposed method and all the
other methods in comparison were assessed using four
measures, namely, sensitivity, specificity, false discovery
rate (FDR) and false non-discovery rate (FNR) based on
500 independent Monte-Carlo iterations. We compared
the performances of all the methods mentioned above
under the following simulation scenarios for the three
settings:
Unequal sample sizes of the two subject groups

When the number of samples in the two groups were
unequal, we considered the total effective sample size for
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the experiment as

1
n1

4
+ n1

. In this simulation scenario, we

2

considered n1 = 30 and n2 = 70 in each experiment.
Therefore, the total effective sample size for experiment i
is Ni = 1 4 1 = 84 , i = 1, 2, …, K. Table 1 shows the FDR
n1 + n2

values for our proposed method and all the other methods in comparison, for the three simulation settings.
We observe that in setting 1, where there exists no
hidden variable or confounder, all methods, including
our proposed method, have reasonably small FDR values. But in setting 2, where there exists a hidden effect
of a confounder, the Fisher’s and weighted Z-score
methods without any empirical adjustments perform
very poorly with extremely high FDR values. In the
presence of a hidden variable which does not act as confounder in setting 3, all methods performed similarly,
except EAMA which had slightly higher FDR (0.11)
compared to the other methods. Figure 1 shows the
sensitivity, specificity, and FNR values of our proposed
method and all the other methods in comparison, for
the three simulation settings. We observed that all the
methods have very similar sensitivity and FNR values in
all settings. The specificity values of all methods, except
the Fisher’s and weighted Z-score methods without any
empirical adjustments, are also similar in all settings.
The Fisher’s and weighted Z-score methods have low
specificity values in setting 2 in the presence of hidden
confounder.
Table 1 FDR of our proposed meta-analysis method (BACON
adjusted Weighted Z) and the other methods in comparison with
unequal sample sizes of the subject groups
Setting

Method

FDR

1

Fisher

0.05

EAMA

0.05

BACON adjusted Fisher

0.05

weighted Z

0.05

EB adjusted weighted Z

0.06

BACON adjusted weighted Z

0.05

Fisher

0.83

EAMA

0.06

BACON adjusted Fisher

0.02

weighted Z

0.90

EB adjusted weighted Z

0.05

BACON adjusted weighted Z

0.04

Fisher

0.05

EAMA

0.11

BACON adjusted Fisher

0.06

weighted Z

0.05

EB adjusted weighted Z

0.02

BACON adjusted weighted Z

0.05

2

3
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Fig. 1 Performances of the meta-analysis methods in terms of sensitivity, specificity, and FNR with unequal sample sizes of the subject groups. This
figure shows the average sensitivity, specificity, and FNR values over 500 independent Monte-Carlo iterations of the proposed method and all the
other methods in comparison. Results are shown for all three simulation settings. The sample sizes of the two subject groups in each experiment
are 30 and 70

Varying sample sizes of experiments

In this simulation scenario, we considered varying sample
sizes of the experiments. We considered Ni = Ni − 1 + 10,
i = 2, …, K and N1 = 80. The subjects were equally divided
between the two groups. Table 2 shows the FDR values
for the three simulation settings under this scenario.
The results were very similar to what we observed
before with varying sample sizes in the subject groups

for all methods in all three settings, where the Fisher’s
method and weighted Z-score method, without empirical
adjustments, had very high FDR values in setting 2, and
the FDR of EAMA was slightly high (0.12) in presence of
a hidden variable which does not act as confounder. The
sensitivity, and FNR values were similar for all methods
in all settings, while the specificity values of the Fisher’s
method and weighted Z-score method, without empirical
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Table 2 FDR of our proposed meta-analysis method (BACON
adjusted Weighted Z) and the other methods in comparison with
unequal sample sizes of the experiments

Table 3 FDR of our proposed meta-analysis method (BACON
adjusted Weighted Z) and the other methods in comparison with
reduced and unequal sample sizes of the experiments

Setting

Method

FDR

Setting

Method

FDR

1

Fisher

0.05

1

Fisher

0.06

EAMA

0.06

EAMA

0.09

BACON adjusted Fisher

0.05

BACON adjusted Fisher

0.06

weighted Z

0.05

weighted Z

0.05

EB adjusted weighted Z

0.03

EB adjusted weighted Z

0.02

BACON adjusted weighted Z

0.05

BACON adjusted weighted Z

0.05

Fisher

0.89

Fisher

0.68

EAMA

0.05

EAMA

0.03

BACON adjusted Fisher

0.03

BACON adjusted Fisher

0.03

weighted Z

0.90

weighted Z

0.86

EB adjusted weighted Z

0.06

EB adjusted weighted Z

0.13

BACON adjusted weighted Z

0.04

BACON adjusted weighted Z

0.05

Fisher

0.05

Fisher

0.05

EAMA

0.12

EAMA

0.06

BACON adjusted Fisher

0.05

BACON adjusted Fisher

0.05

weighted Z

0.05

weighted Z

0.05

EB adjusted weighted Z

0.03

EB adjusted weighted Z

0.06

BACON adjusted weighted Z

0.05

BACON adjusted weighted Z

0.05

2

3

adjustments, were very low in setting 2 (supplementary
Fig. 1).
Since in many biological experiments the sample sizes
are lower, we reduced the sample sizes of the experiments and compared the performances of the methods.
We considered Ni = Ni − 1 + 6, i = 2, …, K and N1 = 20. The
FDR values for the three settings are shown in Table 3.
In setting 1, the FDR values of all the methods, except
EAMA, were similar, where EAMA tends to have slightly
high value (0.09). In setting 2, the performances of the
Fisher’s method and the weighted Z-score method, without empirical adjustments, were consistently poor in the
presence of hidden confounder. Additionally, the performance of the EB-adjusted weighted Z-score method gets
worse with higher FDR (0.13). In setting 3, the FDR values of all the methods were similar. The sensitivity, specificity, and FNR values of all methods were very similar to
what we observed before (supplementary Fig. 2).
Additionally, we considered a simulation scenario
where different set of genes were differentially expressed
across the experiments. We considered 500 genes as differentially expressed in the first five experiments and a
separate set of 500 genes as differentially expressed in
the remaining five experiments. This resulted in a total
of 1000 genes as differentially expressed in at least one
experiment. The sample sizes of the experiments were
Ni = Ni − 1 + 6, i = 2, …, K and N1 = 20. All the other
choices of the parameters were same as before in all three
settings. Supplementary table 1 shows the performances

2

3

of all the methods in all three settings based on 500
Monte-Carlo iterations. We observed very similar performances of all the methods as we observed in the previous scenario with same genes as differentially expressed
across experiments.
Reduced differential expression between the subject groups

In this scenario, we considered a reduced magnitude in
differential expression of the genes between the two subject groups. To achieve this, the interaction terms were
generated so that the absolute differences in the log
expression values of the 1000 differentially expressed
genes between the two groups was two and for all the
remaining genes was zero. Additionally, we considered
varying sample sizes of the experiments as we previously
observed differences in performances of the methods
under this scenario. We considered Ni = Ni − 1 + 10, i = 2,
…, K and N1 = 80. The results are shown in Table 4.
In setting 1, all methods perform well, except EAMA,
which had slightly high FDR (0.09). Both EB adjusted
weighted Z and our proposed method performed similar,
however, the former had a slightly high FDR (0.06) in setting 1. In setting 2, where there exists an effect of hidden
confounder, huge differences in the performances can be
observed. Specifically, Fisher’s method and the weighted
Z-score method without any empirical adjustments had
very poor performances with low sensitivity and specificity values, and high FDR and FNR values. EAMA had
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low sensitivity and high FNR values, and the BACONadjusted Fisher method had low sensitivity value. But
both EB-adjusted weighted Z and our proposed method
performed similarly. In setting 3, in presence of hidden
variable which does not act as confounder, all methods
had very similar performances.
Overall, summarizing from all the simulation results,
we find that our proposed BACON adjusted weighted
Z-score method has been the most consistent in

maintaining the high levels of sensitivity and specificity
while maintaining low or acceptable levels of false positive and false negative. Although EB-adjusted weighted
Z is a good competitor of BACON adjusted weighted
Z in terms of sensitivity, specificity, and FNR values,
there exist instances in presence of hidden confounder
(Table 3, and supplementary table 1) where EB-adjusted
weighted Z has unacceptable FDR values that are much
higher than the nominal type-I error rate.

Table 4 Performances of our proposed meta-analysis method
(BACON adjusted Weighted Z) and the other methods in
comparison under reduced differential expressions between
subject groups and varying experiment sample sizes

Lung cancer data

Setting Method

1

2

3

Performance assessment measure
Sensitivity Specificity FDR

FNR

Fisher

1.00

0.99

0.05

0.00

EAMA

1.00

0.99

0.09

0.00

BACON adjusted Fisher 1.00

0.99

0.05

0.00

weighted Z

1.00

0.99

0.05

0.00

EB adjusted weighted
Z

1.00

0.99

0.06

0.00

BACON adjusted
weighted Z

1.00

1.00

0.05

0.00

Fisher

0.44

0.13

0.95

0.34

EAMA

0.40

1.00

0.003 0.34

BACON adjusted Fisher 0.40

1.00

0.02

0.06

weighted Z

0.55

0.01

0.94

0.84

EB adjusted weighted
Z

1.00

1.00

0.04

0.00

BACON adjusted
weighted Z

1.00

1.00

0.02

0.00

Fisher

0.99

1.00

0.05

0.00

EAMA

0.99

1.00

0.02

0.00

BACON adjusted Fisher 0.99

1.00

0.02

0.00

weighted Z

1.00

1.00

0.05

0.00

EB adjusted weighted
Z

1.00

1.00

0.03

0.00

BACON adjusted
weighted Z

1.00

1.00

0.02

0.00

We considered five lung cancer gene expression datasets,
namely Bhattacharjee [23], GSE11969 [24], GSE29016 [25],
GSE30219 [26], and GSE43580 [27]. These datasets were
previously normalized and processed by Hughey JJ et al.
[28] which are available at [29]. Each dataset had normalized gene expression levels for 7200 genes for participants
with different types of lung cancer. We aimed to identify
the set of differentially expressed genes between the participants with Adenocarcinoma (AD) and Squamous
cell carcinoma (SQ). Four of the datasets (GSE11969,
GSE29016, GSE30219, and GSE43580) had information on
the smoking status, gender, and age of the participants. All
participants with missing covariates were removed from
the analysis. Table 5 shows the characteristics of the participants for the two cancer types in each dataset.
We tested for differential expression of the genes
between AD and SQ participants using the ‘limma’ package in Bioconductor [22], adjusting for the available
covariates, for each dataset separately. The raw p-values and the direction of the effects of the genes were
stored for the meta-analysis. We applied our proposed
meta-analysis method to identify the set of differentially
expressed genes between AD and SQ lung cancer participants. The empirically estimated null distribution of the
z-scores, using BACON [19], had mean − 0.34 and standard deviation (SD) 1.91. This suggests that the empirically estimated null distribution of the z-scores is much
deviated from the theoretical null distribution, N(0, 1).
After multiple testing correction with BH method [20],

Table 5 Characteristics of the Adenocarcinoma (AD) and Squamous cell carcinoma (SQ) participants in each of the five lung cancer
datasets
Dataset

Cancer type
N (%)
AD

Bhattacharjee (N = 81)

GSE11969 (N = 125)

GSE29016 (N = 47)

GSE30219 (N = 145)

GSE43580 (N = 144)

Smoking status
N (%)
SQ

Never

Former

Gender
N (%)
Current

Female

Age
years (mean ± SD)
Male

60 (74.1)

21 (25.9)

–

–

–

–

–

–

90 (72.0)

35 (28.0)

46 (36.8)

–

79 (63.2)

45 (36.0)

80 (64.0)

62.3 ± 9.6

36 (76.6)

11 (23.4)

10 (21.3)

–

37 (78.7)

23 (48.9)

24 (51.1)

84 (57.9)

61 (42.1)

10 (6.9)

68 (46.9)

67 (46.2)

24 (16.6)

121 (83.4)

72 (50.0)

72 (50.0)

28 (19.4)

20 (13.9)

96 (66.7)

27 (18.8)

117 (81.2)

67.3 ±11.0

62.3 ± 9.1

59.5 ± 9.0
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we identified 2957 differentially expressed genes between
AD and SQ participants at 5% significance level.
For comparison, we also applied the naïve weighted
Z-score method as well as our previously proposed
method, EAMA, to identify the set of differentially
expressed genes. The naïve weighted Z-score method
identified 4922 differentially expressed genes, while
EAMA identified 1505 differentially expressed genes,
at BH adjusted p-value cutoff of 0.05. A Venn diagram
showing the overlap of the number of differentially
expressed genes identified by our proposed method with
the other two methods in comparison is given in Fig. 2.
All the genes identified by EAMA were also identified
by both our proposed method and the naïve weighted
Z-score method. Additionally, all the genes identified by
the proposed method were also identified by the naïve
weighted Z-score method. Identification of so many
differentially expressed genes by the naïve weighted
Z-score method indicates possibility of high gross false
discoveries. EAMA identified much lesser number of
genes compared to our proposed method at the same
BH adjusted p-value cutoff, which might reflect a situation where EAMA has lower sensitivity and/or high non
false discovery rate, similar to setting 2 in Table 4. We
also checked the performances of the methods without
adjusting for the covariates in the studies, assuming they
are hidden. The pattern of performances of the methods
were very similar to what we observed after adjusting
for the observed covariates, where the naïve weighted
Z-score method identified a large number of differentially
expressed genes and EAMA identified much lesser number of genes compared to our proposed method. Note
that, even after adjusting for the observed covariates,

there still might exist potential hidden confounders
underlying these studies which remained unaccounted
for in all our analyses. We proceed with the results
adjusting for the covariates with the aim to account for all
possible covariates effects that have been observed.
In order to identify biological pathways associated with
the significant list of genes identified by all three methods, we performed functional annotation analysis using
the software, called DAVID [30, 31]. Some of the top
pathways overrepresented in the significant list of genes
include cell cycle, DNA replication, pathways in cancer,
and p53 signaling pathway, which has been frequently
found to be associated with lung cancer [32–34]. We also
identified the pathways overrepresented in the significant list of genes identified only by our proposed method.
Pathways related to lung cancer, such as non-small cell
lung cancer and Foxo signaling pathway [35], were significantly overrepresented in our gene list.

Discussion
Meta-analysis is a popular tool for combining hypothesis testing results from multiple studies. It is extensively
used in genomic studies, clinical studies, psychological
studies, and other social sciences applications. The field
of genomic experiments have undergone major changes
in the past few years with the advent of modern highthroughput technologies. One such change is that thousands of genes can be analyzed simultaneously nowadays
which, in turn, leads to simultaneous testing of thousands
of hypotheses. While combining such large-scale multiple hypotheses testing results from multiple studies, the
traditional meta-analysis approaches involving p-value
combinations fail to make use of the large-scale aspect

0

EAMA

1965

0

Weighted Z

1505

J

O

1452

0

Proposed method
Fig. 2 Venn diagram showing the number of differentially expressed genes identified by the meta-analysis methods. This figure shows the overlap
between the number of differentially expressed genes, significant at BH-adjusted p-value cutoff of 0.05, identified by the proposed method, the
naïve weighted Z-score method and EAMA
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of the data. For instance, large-scale hypotheses testing
allows empirical estimation of the parameters of null distributions without having to rely on some theoretically
set null parameters. However, such provisions of empirically adjusting the null distributions are not accommodated by the classical p-value combination methods. A
possible consequence of relying only on theoretical null
distributions can be gross false discoveries and inaccurate
inference from meta-analysis. As discussed in this article,
this problem becomes more profound whenever there is
a possibility of presence of some unobserved variables
or unmeasured confounders. In this article we discussed
some recent developments in estimating empirical null
distributions and proposed ways for incorporating such
empirical null distributions in meta-analysis of largescale genomic experiments. Finally, we proposed an
empirically adjusted weighted p-value combination
approach which estimates the empirical null distribution
parameters through a Bayesian framework. We demonstrated its robustness and superiority over other metaanalysis approaches through a wide variety of simulation
settings that mimic large-scale genomic testing experiments. We also applied our proposed method in metaanalysis of multiple lung cancer gene-expression studies
to obtain biologically meaningful results. Although we
mostly focused on microarray studies in this article, our
proposed method can be easily applied for meta-analysis
of expression data from other platforms (e.g., next-generation sequencing) or other type of genomic studies (e.g.,
DNA methylation, SNP data) as long as one can obtain
p-values for each genomic feature from multiple studies.
The proposed method assumes a common null distribution across all studies, which is estimated empirically instead of relying on a theoretical null distribution.
There exist meta-analysis methods that do not necessarily assume a common null distribution to account for
between studies variability. However, such methods are
primarily model-based approaches, e.g., random effects
model, which is a different category of meta-analysis that
requires information on the individual effect sizes and
their corresponding standard errors to obtain a measure
of between-study variability [36]. In many situations, the
individual effect size estimates and the corresponding
standard errors are not available. Therefore, in this article, we have focused on those meta-analysis methods that
require only p-values from individual studies.
In this article we aimed at improving the meta-analysis
method of large-scale genomic testing studies by modifying the classical p-value combination methods through
empirical adjustments. These classical p-value combination methods aim to test for significance of a gene in
at least one of the component studies and the method
proposed in this article is based on the same principle
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of significance testing. There exists another approach of
meta-analysis of significance testing results that focuses
on testing for significance of a gene in the majority (e.g.,
70%) of the component studies. There have been some
recent p-value combination methods that aimed for this
second type of meta-analysis [11, 37]. Since these methods test hypotheses which are conceptually different
from the hypotheses we are testing and have a different
aim, we have not discussed them in this article. Nevertheless, the empirical adjustments, which we applied in our
meta-analysis method, can also be extended to the metaanalysis methods of the second type if the main aim is to
find significant genes in the majority of component studies. In future, we plan to pursue this approach of empirical adjustments to the second type of meta-analysis.

Conclusion
In this article, we have highlighted the drawbacks of the
classical p-value combination methods for significance
testing in large-scale genomic experiments. These classical p-value combination methods rely on a theoretical
null distribution which can be different from the true
null distribution especially in the presence of confounding variables in large observational studies. We have
proposed a robust meta-analysis approach of p-value
combination which modifies the p-values through the
computation of an empirical null distribution. Our proposed meta-analysis approach can account for the effects
of unobserved variables and confounders and has been
shown to perform better than the classical p-value combination methods and other competing meta-analysis
techniques. Overall, we believe that our proposed metaanalysis approach can help in accurate identification of
truly significant genes by combining the findings of multiple large-scale genomic experiments.
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